Fertility warning
This medicine may affect fertility.
Leaflet MELFALAN ZENTIVA 50mg powder and solvent for solution for injection / infusion
Precautions:
Dose adjustment in hepatic impairment
Dose adjustment may be needed in liver disease.
Cytotoxic / special handling
Handle with special care.
Contraception required
Effective contraception is required during treatment.
Contraindicated during breastfeeding
Do not use this medicine while breastfeeding.
Contraindicated during pregnancy
Do not use this medicine during pregnancy.
Hepatotoxicity
This medicine may affect the liver.
Major drug interactions
This medicine may have important interactions with other medicines.
Myelosuppression / agranulocytosis
This medicine may lower blood cell counts.
Additional monitoring
This medicine is subject to additional monitoring.
Requires periodic laboratory tests
Periodic laboratory tests may be required during treatment.
Severe skin reactions
Stop taking the medicine and seek urgent medical help if a severe rash occurs.
Melphalan is a chemotherapy agent primarily used to treat certain types of cancer, such as multiple myeloma and ovarian cancer. It works by interfering with the DNA of cancer cells, preventing them from dividing and spreading.
Melphalan is administered either orally or intravenously, depending on the type and stage of cancer being treated. The treatment may be associated with side effects such as nausea, vomiting, decreased blood cell counts, and an increased risk of infections.
Patients undergoing melphalan treatment must be closely monitored by their doctor to assess effectiveness and manage any adverse reactions. It is important to strictly follow the prescribed doses.
This medication is used only under strict medical supervision and is not recommended for pregnant or breastfeeding women due to risks to the fetus or child.
Melphalan is administered either orally or intravenously, depending on the type and stage of cancer being treated. The treatment may be associated with side effects such as nausea, vomiting, decreased blood cell counts, and an increased risk of infections.
Patients undergoing melphalan treatment must be closely monitored by their doctor to assess effectiveness and manage any adverse reactions. It is important to strictly follow the prescribed doses.
This medication is used only under strict medical supervision and is not recommended for pregnant or breastfeeding women due to risks to the fetus or child.
General data about MELFALAN ZENTIVA 50mg
- Substance:
- melphalan
- Date of latest medicines list:
- 01-06-2026
- Product code:
- W68577001
- Concentration:
- 50mg
- Pharmaceutical form:
- powder and solvent for solution for injection / infusion
- Quantity:
- 1
- Product type:
- Generic medicine
- Price:
- 900.51 RON
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Pharmaceutical forms available for melphalan
Concentrations available for melphalan
- 200mg
- 2mg
- 50mg